SPY003
Sponsors
Spyre Therapeutics Inc., Spyre Therapeutics, Inc.
Conditions
ColitisColitis, UlcerativeInflammatory Bowel DiseasesUlcerative ColitisUlcerative colitis (Inflammatory Bowel Disease)
Phase 2
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
RecruitingNCT07012395
Start: 2025-05-27End: 2028-03-01Target: 645Updated: 2026-08-25
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
Not yet recruitingCTIS2025-524640-35-00
Target: 102Updated: 2026-06-17
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
Enrolling by invitationNCT07652294
Start: 2026-06-08End: 2030-01-03Target: 645Updated: 2026-09-15